Efficacy and safety of Ding-Kun-Dan for female infertility patients with predicted poor ovarian response undergoing in vitro fertilization/intracytoplasmic sperm injection: study protocol for a randomized controlled trial

• Published in: Current controlled trials in cardiovascular medicine Vol. 19; no. 1; p. 124
• Main Authors: Ma, Saihua, Ma, Ruihong, Xia, Tian, Afnan, Masoud, Song, Xueru, Xu, Fengqin, Hao, Guimin, Zhu, Fangfang, Han, Jingpei, Zhao, Zhimei
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 20.02.2018; BioMed Central; BMC
• Subjects: Adult; Chinese medicine; Clinical Trials, Phase III as Topic; Data Interpretation, Statistical; Diminished ovarian reserve; Ding-Kun-Dan; Drug dosages; Female; Fertilization in Vitro; Health aspects; Hospitals; Humans; In vitro fertilization; Infertility; Infertility, Female - blood; Infertility, Female - drug therapy; Medicine, Chinese; Medicine, Chinese Traditional - adverse effects; Menstruation; Multicenter Studies as Topic; Ovaries; Ovulation; Poor ovarian reserve; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic; Safety and security measures; Sample Size; Sperm; Sperm Injections, Intracytoplasmic; Study Protocol; TCM; Traditional Chinese medicine; China; ICSI; Diminished ovarian reserve; Infertility; IVF; Traditional Chinese medicine; Assisted reproductive technology; Poor ovarian reserve; Ding-Kun-Dan; TCM
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-018-2511-0

Women undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) who have a predicted poor ovarian response (POR) present a challenge for reproductive medicine specialists. Traditional Chinese medicine (TCM) is commonly used in China for such patients, in the belief that it will improve the ovarian response and ultimately increase pregnancy rates. However, there is a lack of high-quality evidence about the effect of TCM on improving ovarian response in such patients. The purpose of this study is to evaluate ongoing viable pregnancy rate at 12 weeks' gestation and related indicators of ovarian response in fertile women who have a predicted poor ovarian response having immediate versus delayed IVF/ICSI after 3 months of Ding-Kun-Dan (DKD) pre-treatment. This study is a multicenter, randomized controlled, parallel-group, phase III, superiority clinical trial. Two hundred and seventy-eight eligible female infertility patients with POR will be included in the study and randomly allocated into an immediate treatment group and a DKD group in a 1:1 ratio. Both groups will receive IVF or ICSI as a standard treatment while in the DKD group, a commercially available Chinese medicine, DKD, will be administrated for 3 months before the IVF/ICSI cycle starts. The primary outcome of the study is the ongoing pregnancy rate at 12 weeks' gestation. The secondary outcomes include total gonadotropin dosage, duration of stimulation, estradiol (E ) and progesterone (P) levels on human chorionic gonadotropin (hCG) trigger day, cycle cancellation rate, number of oocytes retrieved, high-quality embryo rate, biochemical pregnancy rate, the change of serum anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), and E levels and all side effects, safety outcomes, and any adverse events. The protocol was approved by the Ethics Committee of the First Teaching Hospital of Tianjin university of TCM (approval no. TYLL2017[K] 004). IVF/ICSI is increasingly used to treat couples desiring a baby. Many of these women will have poor ovarian function. In China, DKD is commonly used for these patients prior to undergoing IVF/ICSI. There is no effective treatment for poor ovarian response in Western medicine currently. It is important, therefore, to undertake this randomized control trial to determine whether DKD is effective or not. Chinese Clinical Trial Registry, ID: ChiCTR-IOR-17011697 . Registered on 19 June 2017.